1. Gipuzkoa Alzheimer Project (Basque cohort)

The Gipuzkoa Alzheimer Project (PGA) is a longitudinal study on pre-clinical Alzheimer's disease.

Principal Researcher Dr. Pablo Martinez-Lage

Status: Ongoing:

The initial project and the 2014 amendment have been approved by the Gipuzkoa clinical research ethics committee.

Purpose: To characterize pre-clinical Alzheimer's disease in a cohort of paucisymptomatic or cognitively healthy men and women from 40 to 80 years of age and to investigate biomarkers and risk factors to help lay the groundwork for future programs for the prevention of this disease.

Basque cohorts: In 2011, CITA-alzheimer recruited a sample of 500 volunteers from the community through announcements in the local press and after the presentation of the project in the Association of Relatives of patients with Alzheimer's disease of Gipuzkoa (AFAGI). After the implementation of the corresponding criteria of inclusion/exclusion, the Basque cohort ended up being composed of 408 people (55% women) with an average age of 58 years. Half of the participants have a history of dementia in a direct family member. 25% of the sample are carriers of APOE4.

Evaluation: The following was performed on all the participants: 1 - illness evaluation (cardiovascular data, anthropometrics, general mental function); 2. neurological evaluation (medical history, family history, cognitive symptoms , behavioural and psychological symptoms, cognitive and neurological exploration, CDR, functional capacity); 3 neuro-psychological evaluation (pre-morbid intelligence, memory, language, executive function, visuoperceptive and visuoconstructive capacity, attention/concentration, perceived stress); 4, dietetics/nutrition and lifestyle survey (frequency of food intake, physical activity, sleep quality, leisure activities and productive), 5 structural and functional magnetic resonance in resting states; 6 - collection of biological blood samples (plasma, serum, cell fraction, total blood), urine, and cerebrospinal fluid (60% of the sample)

Follow-up: Scheduled every 3 years for a minimum of 12 years. The first 3-year follow-up visit is currently taking place, which would be completed in June 2015. 75% of the cohort has been longitudinally evaluated to date. The loss of subjects in the follow up stands at 6 %. 90% of people who donated cerebrospinal fluid in the baseline visit did the same in this follow-up visit.


We use own and third party cookies to improve our services and show related advertising to your preferences by analyzing your browsing habits. If you continue browsing, we consider that you accept the use.
You can change the settings or get more information here.